Guilin Sanjin Pharmaceutical Co Ltd (002275) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally.

Total Assets Chart for Guilin Sanjin Pharmaceutical Co Ltd

Guilin Sanjin Pharmaceutical Co Ltd (002275) total assets for FY2025 were CNY 4.3B, a 0.6% change from FY2024. Guilin Sanjin Pharmaceutical Co Ltd's total assets grew from CNY 831.8M in 2006 to CNY 4.3B in 2025 (411.9% over 19 years). Total assets compound annual growth rate: 5-year CAGR of 1.9%, 10-year CAGR of 4.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥7.27B
Implied Share Price
¥12.37
Enterprise Value
¥6.20B
Revenue (TTM)
¥2.02B
EBITDA
¥646.32M
Profit Margin
20.19%
Trailing P/E
17.93
Forward P/E
19.96
Price/Book (MRQ)
2.23
Price/Sales (TTM)
3.61
EV/EBITDA
9.22
EV/Revenue
3.07
Dividend Yield
4.02%
Book Value
¥5.51
Free Cash Flow (FY2025)
¥621.18M
Free Cash Flow Yield
8.55%

Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.